分化型甲状腺癌幸存者不良心血管结局风险:系统综述与荟萃分析
该系统综述与荟萃分析比较分化型甲状腺癌(DTC)幸存者与一般人群的心血管死亡与发病风险,检索5个电子数据库(建库至2021年10月),纳入7项研究。
要点
- 缺血性心脏病、卒中、心力衰竭风险未见显著升高,多数分析存在显著异质性。
核心结论
- 有限证据提示,校正混杂因素后DTC幸存者心血管死亡与心房颤动风险可能升高。
- 未观察到缺血性心脏病、卒中或心力衰竭风险显著升高。
- 多数分析存在显著异质性,需进一步研究并关注心血管危险因素以明确DTC幸存者的心血管风险。
研究设计与样本
- 系统综述与荟萃分析,检索5个电子数据库(建库至2021年10月)并辅以手工检索。
- 由两名评价者独立筛选文献、审阅全文、提取数据并评价研究质量,分歧由第三名评价者解决。
- 共筛选3409条唯一题录、审阅65篇全文,最终纳入7项研究。
- 主要结局为心血管死亡,次要结局包括心房颤动、缺血性心脏病、卒中和心力衰竭。
- 采用随机效应模型估计相对危险度(RR)及置信区间(CI),并与一般人群比较,模型校正年龄和性别;对校正混杂因素的数据与粗数据分别进行荟萃分析。
临床怎么用
- 原文未据此给出推荐。
局限性
- 多数分析存在显著异质性(心房颤动I²=75%、卒中I²=69%、心力衰竭I²=79%)。
- 证据有限(limited evidence),需进一步研究并仔细关注心血管危险因素,以明确DTC幸存者的心血管风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Introduction: Long-term cardiovascular (CV) risk is a concern for differentiated thyroid cancer (DTC) survivors. Methods: We performed a systematic review and meta-analysis evaluating the risks of CV mortality and morbidity in DTC survivors compared with the general population. Respective meta-analyses were conducted for data that were adjusted for relevant confounders and crude data. We searched five electronic databases from inception to October 2021, supplemented with a hand search. Two reviewers independently screened citations, reviewed full text articles, extracted data, and critically appraised the studies, with discrepancies resolved by a third reviewer. The primary outcome was CV mortality. Secondary outcomes included atrial fibrillation, ischemic heart disease, stroke, and heart failure. We estimated the relative risk (RR) and confidence intervals [CI] of outcomes using random-effects models (adjusted for age and gender), compared with the general population. Results: We reviewed 3409 unique citations, 65 full text articles, and included 7 studies. CV mortality risk was significantly increased in DTC survivors in one study adjusted for confounders-adjusted RR (aRR) 3.35 ([CI 1.66-6.67]; 524 DTC, 1572 controls). The risk of CV morbidity in DTC survivors, adjusted for risk factors, was estimated as follows: atrial fibrillation-aRR 1.66 [CI 1.22-2.27] (3 studies, 4428 DTC, I2 = 75%), ischemic heart disease-aRR 0.97 [CI 0.84-1.13] (2 studies, 3910 DTC, I2 = 0%), stroke-aRR 1.14 [CI 0.84-1.55] (2 studies, 3910 DTC, I2 = 69%), and heart failure-aRR 0.98 [CI 0.60-1.59] (2 studies, 3910 DTC, I2 = 79%). In meta-analyses of unadjusted data, the risks of CV mortality were not significantly increased but the CV morbidity risks were similar to adjusted data. Conclusions: There is limited evidence suggesting that DTC survivors may be at an increased risk of CV death and atrial fibrillation (after adjustment for confounders). We did not observe a significantly increased risk of ischemic heart disease, stroke, or heart failure. Most analyses were subject to significant heterogeneity and further research, with careful attention to CV risk factors, is needed to clarify CV risk in DTC survivors. Registration: PROSPERO CRD42021244743.
引用
- Qiang JK, Alwithenani R, Uleryk E, et al. Risk of Adverse Cardiovascular Outcomes in Differentiated Thyroid Cancer Survivors: A Systematic Review and Meta-Analysis. Thyroid. 2022. PMID: 36074932. doi:10.1089/thy.2022.0209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。